Lack of association of the plasminogen activator inhibitor-1 4G/5G promoter polymorphism with cardiovascular disease in the elderly

被引:32
作者
Crainich, P
Jenny, NS
Tang, Z
Arnold, AM
Kuller, LH
Manolio, T
Sharrett, AR
Tracy, RP
机构
[1] Univ Vermont, Coll Med, Dept Pathol, Burlington, VT 05405 USA
[2] Univ Washington, Dept Biostat, Seattle, WA 98195 USA
[3] Univ Pittsburgh, Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15260 USA
[4] NHLBI, Div Epidemiol & Clin Applicat, NIH, Bethesda, MD 20892 USA
[5] Johns Hopkins Univ, Sch Publ Hlth Epidemiol, Baltimore, MD USA
[6] Univ Vermont, Dept Biochem, Burlington, VT 05405 USA
关键词
cardiovascular disease; elderly; fibrinolysis; genetic polymorphism; plasminogen activator inhibitor-1;
D O I
10.1046/j.1538-7836.2003.00255.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Elevated circulating plasminogen activator inhibitor-1 (PAI-1) may increase risk of cardiovascular disease (CVD). The 4G allele of the 4G/5G PAI-1 promoter polymorphism is associated with higher levels of PAI-1. We examined the association of PAI-1 4G/5G genotype and CVD events in the elderly participants of the Cardiovascular Health Study (CHS). We measured 4G/5G genotype in a nested case-control study within the CHS. Cases included incident angina, myocardial infarction (MI), and stroke. 4G/5G genotype was not found to be associated with markers of fibrinolysis or CVD risk in the selected elderly cohort. There were no differences in genotype frequencies by case-control status (5G/5G frequency 16-22%; chi(2) P = 0.07). The 5G allele was not associated with incident CVD events when individuals with at least one 5G allele were compared to 4G/4G homozygotes, The presence of at least one 4G allele was likewise not associated with incident CVD when those with 4G/4G and 4G/5G genotypes were compared to 5G/5G homozygotes. Our results suggest that the PAI-1 4G/5G promoter polymorphism is not associated CVD risk factors or incident CVD events in the elderly.
引用
收藏
页码:1799 / 1804
页数:6
相关论文
共 39 条
  • [1] Lack of association of a common polymorphism of the plasminogen activator inhibitor-1 gene with coronary artery disease and myocardial infarction
    Anderson, JL
    Muhlestein, JB
    Habashi, J
    Carlquist, JF
    Bair, TL
    Elmer, SP
    Davis, BP
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1999, 34 (06) : 1778 - 1783
  • [2] Ardissino D, 1999, BLOOD, V94, P46
  • [3] Bladbjerg EM, 1999, THROMB HAEMOSTASIS, V82, P1100
  • [4] Genetic variation in coagulation and fibrinolytic proteins and their relation with acute myocardial infarction
    Boekholdt, SM
    Bijsterveld, NR
    Moons, AHM
    Levi, M
    Büller, HR
    Peters, RJG
    [J]. CIRCULATION, 2001, 104 (25) : 3063 - 3068
  • [5] Infarctlike lesions in the brain: Prevalence and anatomic characteristics at MR imaging of the elderly - Data from the cardiovascular health study
    Bryan, RN
    Wells, SW
    Miller, TJ
    Elster, AD
    Jungreis, CA
    Poirier, VC
    Lind, BK
    Manolio, TA
    [J]. RADIOLOGY, 1997, 202 (01) : 47 - 54
  • [6] Amelioration of the inhibition of fibrinolysis in elderly, obese subjects by moderate energy intake restriction
    CallesEscandon, J
    Ballor, D
    HarveyBerino, J
    Ades, P
    Tracy, R
    Sobel, B
    [J]. AMERICAN JOURNAL OF CLINICAL NUTRITION, 1996, 64 (01) : 7 - 11
  • [7] Catto AJ, 1997, THROMB HAEMOSTASIS, V77, P730
  • [8] CUSHMAN M, 1995, CLIN CHEM, V41, P264
  • [9] Fibrinolytic activation markers predict myocardial infarction in the elderly - The cardiovascular health study
    Cushman, M
    Lemaitre, RN
    Kuller, LH
    Psaty, BM
    Macy, EM
    Sharrett, AR
    Tracy, RP
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1999, 19 (03) : 493 - 498
  • [10] THE STATUS OF PAI-1 AS A RISK FACTOR FOR ARTERIAL AND THROMBOTIC DISEASE - A REVIEW
    DAWSON, S
    HENNEY, A
    [J]. ATHEROSCLEROSIS, 1992, 95 (2-3) : 105 - 117